Altimmune, Inc., a biopharmaceutical company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC) on March 27, 2024. This filing pertains to the registration of an additional 3,055,006 shares of common stock under the company's 2017 Omnibus Incentive Plan. The plan allows for an automatic annual increase in the number of shares available for issuance, which is determined on January 1 of each year, based on a set formula. The newly registered shares are of the same class as those previously registered under the 2017 Plan. Altimmune's CEO, Dr. Vipin K. Garg, along with other executives and directors, have signed the Registration Statement, indicating their compliance with the requirements for filing on Form S-8.

Altimmune, Inc., a biopharmaceutical company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC) on March 27, 2024. This filing pertains to the registration of an additional 3,055,006 shares of common stock under the company's 2017 Omnibus Incentive Plan. The plan allows for an automatic annual increase in the number of shares available for issuance, which is determined on January 1 of each year, based on a set formula. The newly registered shares are of the same class as those previously registered under the 2017 Plan. Altimmune's CEO, Dr. Vipin K. Garg, along with other executives and directors, have signed the Registration Statement, indicating their compliance with the requirements for filing on Form S-8.